Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3429 participants.
Also called NCT02193971
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,429 participants
- Registry
-
NCT02193971
-
- Other papers using this trial's data
- Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS Trial
- Durable-polymer versus biodegradable-polymer drug-eluting stents in acute coronary syndromes: three-year outcomes of the HOST REDUCE POLYTECH RCT Trial
- Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial
- Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02193971. Randomized; no masking; primary purpose treatment. Start 2014-07 (actual); primary completion 2020-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)
- Condition
- Acute Coronary Syndrome
- Intervention (Device)
- BS-DES (Biostable polymer drug-eluting stent)
- Intervention (Device)
- BD-DES (Biodegradable polymer drug-eluting stent)
- Intervention (Drug)
- Prasugrel 5mg
- Lead sponsor
- Seoul National University Hospital
- Collaborator
- Boston Scientific Korea Co. Ltd
- Collaborator
- Dio
- Collaborator
- Terumo Corporation
- Collaborator
- Abbott
Record details
- Record id
cardio:ct-nct02193971- Content hash
b6e4c4d39e17822a6df11af46108cf73e3cdeb2905c85ab1f2d42ef8bd106ad6